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Abstract
Increased expression of the voltage-gated potassium channel Kn1.3 on activated effector memory T cells (TEM) is associated
with pathology in multiple sclerosis (MS). To date, most studies of Kn1.3 channels in MS have focused on CD4+ TEM cells.
Much less is known about the functional relevance of Kv1.3 on CD8+ TEM cells. Herein, we examined the effects of Kn1.3
blockade on CD8+ T cell proliferation, differentiation into cytotoxic effector cells, and release of granzyme B (GrB), a key
effector of CD8+ T cell-mediated cytotoxicity. We confirmed the expression of Kv1.3 channels on activated human CD8+ T
lymphocytes by immunofluorescent staining. To test the functional relevance of the Kv1.3 channel in CD8+ T cells, we
inhibited this channel via pharmacological blockers or a lentiviral-dominant negative (Kv1.xDN) approach and determined
the effects of the blockade on critical pathogenic parameters of CD8+ T cells. We found that blockade of Kv1.3 with both
lentivirus and pharmacologic agents effectively inhibited cytotoxic effector memory cells’ proliferation, secretion of GrB, and
their ability to kill neural progenitor cells. Intriguingly, the KvDN transduced T cells exhibited arrested differentiation from
central memory (TCM) to effector memory (TEM) states. Transduction of cells that had already differentiated into TEM with
KvDN led to their conversion into TCM. CD8+ TEM have a critical role in MS and other autoimmune diseases. Our present
results indicate a critical role for Kv1.3 in the conversion of CD8+ T cells into potential pathogenic effector cells with
cytotoxic function.
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Introduction
T cell activation and proliferation rely on the sustained influx of
calcium through the calcium release activated calcium (CRAC)
channels for efficient signal transduction and gene transcription.
Two types of K+ channels, termed voltage-gated Kn1.3 and Ca2+-
activated KCa3.1 (also known as IKCa1), contribute to the control
of calcium signaling by providing the electrical driving force for
calcium entry. Kn1.3 channels are activated by depolarization of
the membrane and restore the resting membrane potential of T
cells by an outward flux of potassium ions [1]. KCa3.1 channels,
on the other hand, are initially activated by the rise of the cytosolic
free calcium concentration and consequently hyperpolarize the
membrane, resulting in enhanced calcium influx [1]. The
operation of K+ channels controlling calcium signaling depends
on which channel dominates in the cells.
There are four distinct CD8+ T cell subsets, naı¨ve
(CD45RA+CCR7+), central memory (TCM, CD45RA2CCR7+)
and effector memory (TEM) subsets composed of CD45RA-TEM
(TEM, CD45RA2CCR72) and CD45RA+ TEM (TEMRA,
CD45RA+CCR72), which display differential expression of
Kn1.3 and KCa3.1 channels depending on their state of activation
and differentiation. In the absence of substantial stimulatory
signals, all CD8+ T cell subsets in their quiescent state express
a comparable number of Kn1.3 and KCa3.1 channels, with Kv1.3
channels five- to fifty-fold more abundant than KCa3.1 [1,2,3,4].
Upon activation and subsequent differentiation of naı¨ve and TCM
CD8+ T cells into effector cells, KCa3.1 channels are rapidly and
significantly augmented relative to Kn1.3, thus acting as the
predominant functional K+ channel in activated naı¨ve and TCM
subsets. In contrast, activation of TEM CD8+ T cells substantially
increases the numbers of Kn1.3 channels, but does not signifi-
cantly change the levels of KCa3.1; thus, the numbers of active K+
channels may be a specific functional marker that could
distinguish effector capacities. Since Kv1.3 channels are function-
ally dominant in activated TEM T cells, while KCa3.1 channels are
dominant in activated naı¨ve and TCM T cells it is possible to target
these subsets differentially by administration of specific K+
channel blockers [1,2,3,4].
While MS has traditionally been thought to be mediated by
CD4+ T cells, increasing evidence suggests that infiltrating CD8+
T cells may be a key factor in mediating CNS damage. For
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example, infiltrating CD8+ cells were found to be 10-fold more
abundant than CD4+ T cells in MS brain lesions [5], while
expanded CD8+ T cells persist in the CSF [6] and dominate the T-
cell infiltrate in MS brain tissue [7,8]. Adoptive transfer of CD8+ T
cells reactive to MBP [9,10] or MOG [11] was found to be
capable of inducing severe EAE in animal models, and CD8+ T
cell lines recognizing MBP derived from MS patients were able to
cause injury to oligodendrocytes [12]. In addition, persistently
expanded CD8+ T cells present at high density in the CSF of MS
patients express a memory phenotype, and the CD8+ cytotoxic T
cell response to MBP is increased in MS patients compared to
healthy controls [8,12].
The signals that lead to the development of pathogenic CD8+ T
cells are not well understood. Our previous findings showed that
the infiltrating CD8+ cells with effector memory phenotype in MS
brain tissue expressed high levels of the Kn1.3 channel [13]. We
thus hypothesize that the activated autoreactive TEM of both the
CD4+ and CD8+ T cells expressing a Kn1.3high phenotype may
play an important pathogenic role in MS, possibly by exhibiting
cytotoxic functions responsible for axonal damage [14].
One likely mechanism by which both CD4+ and more so CD8+
T cells induce damage in MS is through the release of granzyme B
(GrB). GrB-expressing CTLs within actively demyelinating lesions
were frequently found in close proximity to injured axons [14].
Activated CD8+ T cells were shown to induce neuronal toxicity by
releasing GrB and this was reversed by specific GrB immundeple-
tion [15,16], indicating that release of this molecule may be
important mechanism of neurotoxicity in MS. It is important to
note that since the autoantigen(s) in MS remain unknown and are
likely heterogenous between and even within individual patients,
we chose to activate TEM CD8
+ T cells derived from healthy
controls by crosslinking TCR rather than introducing a bias by
picking specific peptides and types of patients. Our studies provide
proof of concept that signaling through the Kv1.3 channel is
a novel mechanism by which GrB is released and suggest an
additional mechanism by which blockade of this channel might be
therapeutic in MS and other diseases in which cytoxic T cells
damage their target tissue.
Materials and Methods
Cell Isolation and Stimulation
Human peripheral blood mononuclear cells (PBMC) were
isolated from whole blood obtained from 13 healthy volunteer
donors via venipuncture (30 mL total volume), followed by
differential density gradient centrifugation as described previously
[17]. The study was in accordance with the Declaration of
Helinski, approval was obtained from the Johns Hopkins
University Institutional Review Board and all participants gave
their written informed consent.
CD8 subsets were obtained by negative selection using magnetic
microbeads (Miltenyi Biotec, Auburn, CA) according to the
manufacturer’s instructions. The purity of human CD8+ T cells
was consistently .95% as routinely checked by FACS analysis.
Purified CD8+ T cells were adjusted to 1 to 26106/ml in T cell
medium [Iscoves’s modified Dulbecco’s Medium (IMDM) supple-
mented with glutamine (2 mM), penicillin (100 U/ml), strepto-
mycin (100 mg/ml), gentamicin (50 mg/ml) (Biowhittaker, East
Rotherford, NJ) and 5% human serum (Sigma, St. Louis, MO)].
The cells were stimulated with anti-CD3 alone (cells:beads, 1:1) or
anti-CD3/CD28 (cells:beads, 10:1) mAb-conjugated magnetic
beads (Dynal Biotech, Brown Deer, WI). The higher ratio of cells
to beads for anti-CD3 alone as compared to anti-CD3 and anti-
CD28 was necessary to obtain measurable cell activation,
proliferation and granzyme B secretion.
Pharmacologic Channel Blockers
Four K+ channel blockers were used at their IC50s in the
functional assays including: Stichodactyla helianthus toxin (ShK),
a potent Kv1.3 inhibitor [18]; Margatoxin (MgTx), a specific
Kv1.3 inhibitor [19,20]; Charybdotoxin (ChTx), which inhibits
both Kv1.3 [21,22,23] and KCa3.1 [24,25] channels with similar
potency; and 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole
(TRAM-34), which selectively blocks the KCa3.1 channel [26].
Charybdotoxin (ChTx) and margatoxin (MgTx) were purchased
from Alomone Labs (Jerusalem, Israel). ShK and TRAM-34 were
kindly provided by Dr. Michael Pennington (Bachem) and Dr.
Wulff Heike (University of California), respectively.
Immunofluorescence Microscopy
Cells were washed and placed into cytospin funnels and spun
onto glass slides using a cytospin centrifuge (Shandon, Pittsburgh,
PA) at 750 rpm for 5 minutes. Cells were subsequently fixed with
3.7% paraformaldehyde for 15 min. For intracellular staining,
cells were fixed, permeabilized with Cytofix/Cytoperm solution
(PharMingen, San Diego, CA). After thorough washing of cells,
non-specific binding sites were blocked using 0.5% BSA in PBS for
15 min at room temperature. Thereafter, cells were incubated
with rabbit anti-human Kv1.3 (Alomone Labs, Jerusalem, Israel),
mouse anti-human GrB (Caltag Laboratories, San Francisco, CA)
or mouse anti-human CD8 (PharMingen) antibodies for 30 min at
room temperature. Cells were then labeled with appropriate
secondary antibodies conjugated to Alexa Fluor (AF)-488 and AF-
594 (Molecular Probes, Eugene, OR). Cellular nuclei were stained
with 4, 6-diamidino-2-phenylindole (DAPI) (Molecular Probes) at
1 mg/ml for 10 min. After being mounted in Immuno Fluore
medium (ICN Biomedicals, Aurora, OH), images were acquired
by OpenLab software on a Zeiss Axiovert S100 microscope under
100X objective (Carl Zeiss, Thornwood, NY).
Flow Cytometric Analysis and Cell Sorting
Single cell suspensions were prepared and stained as previously
described [2,17]. The monoclonal Abs utilized for the staining
were FITC-anti-CD45RA (PharMingen), PE-anti-CCR7 (Phar-
Mingen), PerCP-anti-CD8 (PharMingen), Cy-Chrome-anti-CD8
(R & D systems), APC-anti-CD45RA (PharMingen), FITC-anti-
CD45RA (PharMingen) and APC-anti-GrB (GB12; Caltag,
Burlingame, CA) or appropriate isotype controls. Briefly, cells
were washed twice in PBS/0.5% BSA and incubated with
a mixture of specific Abs against surface molecules for 30 min
on ice. Cells were washed twice again in PBS/0.5% BSA, and
fixed, permeabilized with Cytofix/Cytoperm solution (PharMin-
gen). Subsequently, cells were incubated with APC-anti-GrB Ab or
appropriate isotype control and diluted at 1:200 for 30 min on ice,
washed twice in PBS/0.5% BSA and then analyzed on
a FACSCalibur flow cytometer using CellQuest software (BD
Immunocytometry Systems, San Jose, CA).
The CD8+ cells were separated into naive, TCM, TEM and
TEMRA subsets, by cell sorting using the combination of anti-CD8-
Cy-Chrome, anti-CCR7-PE and anti-CD45RA-FITC mAbs.
Single cell suspensions were stained, and the naive, TCM, TEM
and TEMRA cells within the gate of CD8+ cell population were
sorted based on their differential expression of CCR7 and
CD45RA using a MoFlo MLS high-speed cell sorter (Dako, Fort
Collins, Colorado). The purity of each sorted population was
consistently .95%.
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[3H] Thymidine Incorporation
Freshly isolated CD8+ T cells were pretreated with channel
blockers for 3 h. The cells were then cultured at 26105 cells/well
in triplicate in 96-well flat-bottom plates (Falcon, Franklin Lake,
NJ) in 0.2 ml IMDM/5% human serum/16 penicillin-strepto-
mycin under the stimulation conditions as described above for 4 to
5 days. Cultures were pulsed with 1 mCi of [3H] thymidine
(Amersham Biosciences, Piscataway, NJ) for the final 18 h. Cells
were harvested by a 96-well plate harvester (PerkinElmer, Turku,
Finland), and [3H] thymidine uptake was measured in a liquid
scintillation counter (PerkinElmer).
Lentiviral Transduction of Activated CD8+ T cells
T cells were transduced with a lentivirus construct containing
the GFP reporter gene and a dominant negative (DN) form of the
Kv1.x channel as previously described [27]. The DN Kv1.x
sequence codes for a Kv1.x molecule with a function-blocking
mutation (GYG to AYA) in the pore-forming region, which
prevents formation of the tetrameric complex in the membrane
[28,29]. Its denotion of Kv1.x indicates it affects the Kv1 family,
but since human T cells are only known to express Kv1.3, this
channel is likely to be the only one affected.
To obtain activated CD8+ T cells, highly purified CD8+ and
sorted CD8 subsets were stimulated with anti-CD3/CD28 for
24 h. IL-2 was not added to avoid it’s known effects on bypassing
Kv1.3 signaling. Lentiviral transduction of activated CD8 cells was
performed in 48-well plates containing 2 ml/well of T cell culture
medium in the presence of 8 mg/ml protamine sulfate (Sigma);
cells were mixed with Lenti-GFP or Lenti-DN Kv1.x vector
particles at an MOI of ,5, centrifuged at 2000 r.p.m. for 30 min
at 32uC, and incubated at 37uC. T-cell cultures were maintained
by restimulating every 10 days with anti-CD3/CD28 Abs for 3
weeks. Transduction efficiency was determined at different time
points (days 3, 7, 14 and 21 following infection) by examining GFP
expression by flow cytometry. Non-infected T-cells, cultured under
the same conditions, were used as a negative control for GFP. The
transduction efficiencies were usually ,30% and less than 10% of
the cells died during transduction. We did not observe any
preferential transduction of CD8 cell subsets.
PKH26 Staining
Transduced CD8 T cells were suspended in PBS containing 1%
FCS at a concentration of 107cells/ml and labeled with the
fluorochrome PKH26 (SIGMA). Cells were incubated at 25uC for
5 min with PKH26 at a final concentration of 2 mM, washed twice
with, and then resuspended in IMDM/5% human serum/16
penicillin-streptomycin. Division of cells was measured via dilution
of PKH26 using flow-cytometric analysis after 5 days of culture
under the stimulation conditions as described above.
GrB ELISA Analysis
Supernatants were collected from cultures and were then frozen
at 280uC. The frozen supernatants were thawed at room
temperature and GrB levels were measured with commercial
ELISA assay kit (Cell Sciences, Canton, MA) according to the
manufacturers’ instructions.
Neurotoxicity Assays
Human neural progenitor cells (NPCs) were cultured from
human fetal brain specimens of 7–8 weeks of gestation obtained
from Birth Defects Research Laboratory, University of Washing-
ton, Seattle in accordance with National Institutes of Health (NIH)
guidelines and following approval by the Institutional Review
Board at the Johns Hopkins University and NIH as described
previously [15,16]. NPC were cultured at 16105/ml in neural
differentiation media (DMEM/F12 containing 2% FBS) for
neuronal induction in 96-well plates for seven days and then were
exposed for an additional 24 hours to conditioned media (1:20 to
dilution) from 72 hour activated CD8+ T cells treated with MgTx
or vehicle control. Neurotoxicity was evaluated by using
CellQuanti-BlueTM Cell Viability Assay Kit (BioAssay Systems,
Hayward, CA). CellQuanti-blue solution (10 ul/well) was added
to the cultures and cells were incubated for 30 min. The
fluorescence intensity was then detected at Excitation 530 nm
and Emission 590 nm.
Statistical Analysis
Statistical evaluation of significance between the experimental
groups was determined by Student’s t test. Results were de-
termined to be statistically significant when p#0.05.
Results
Kv1.3 is Upregulated in Activated CD8+ T cells
To quantify the CD8+ T cells expressing Kv1.3 at rest and after
stimulation, freshly purified CD8+ T cells (approximately 60%
TEM/TEMRA) were either left unstimulated or stimulated with
anti-CD3 and anti-CD28 antibodies for 3 days, then immunos-
tained for Kv1.3 and CD8 and analyzed by fluorescence
microscopy. Images shown in Fig. 1A demonstrate that while
resting CD8+ T cells failed to express detectable amounts of Kv1.3,
activation of these T cells with anti-CD3/CD28 resulted in
a strong upregulation of Kv1.3 in the cell membrane, which was
colocalized with the surface CD8 domain. Similar results were also
obtained from anti-CD3 stimulated CD8+ T cells (data not
shown). The frequency of CD8+ T cells expressing membrane
Kv1.3 was significantly increased after stimulation with anti-CD3/
CD28 and anti-CD3 alone (Fig. 1 B and C).
Kv1.3 Blockade Preferentially Suppresses the Proliferation
and Differentiation of TEM Cells
We employed two distinct approaches to assess the functional
relevance of Kv1.3 expression by activated CD8+ cells. First, we
assessed the role of Kv1.3 in proliferation of CD8+ T cells by
blocking Kv1.3 signaling with pharmacologic agents. Purified
CD8+ T cells were stimulated in a dose response (data not shown)
of anti-CD3 or anti-CD3/CD28 in the presence or absence of
blockers: ShK and MgTx (Kv1.3 blockers) or ChTx (Kv1.3 and
KCa3.1 blocker). Cell proliferation of the CD8+ cells was
measured by [3H] thymidine incorporation four days later. As
shown in Fig. 2A, proliferation of CD8 T cells treated with ShK
was markedly reduced compared with that of non-treated cells
when the cells were stimulated with anti-CD3, whereas there were
no significant differences in responses to anti-CD3/CD28 of CD8+
cells between ShK- and non-treated cells. Treatment of CD8+ T
cells with ChTx and MgTx inhibited cell proliferation induced by
both anti-CD3/CD28 and anti-CD3 alone. Since the pharmaco-
logical K+ blockers are rapidly degraded, which limits evaluation
of sustained channel blockade, we sought to utilize an alternate
approach to assess the durable effects of channel blockade on cell
proliferation and differentiation. To this end, purified PKH-
labeled CD8+ T cells were transduced with a GFP-tagged,
lentiviral vector expressing a DN Kv1.x sequence or GFP alone
as a control at saturating concentration (MOI) of LV without
inducing cell death. The proliferative response of these transduced
CD8+ cells was subsequently examined by the PKH26 dilution five
and eleven days later after TCR cross-linking. As shown in
Kv1.3 Function in Human CD8+ T Cells
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Figure 2B, the modification of cells with DNKv decreased the
numbers of divided cells, relative to control modified cells, at both
timepoints. We also analyzed the distribution of subpopulations
among GFP+CD8+ cells seven days after transduction. Of note,
transduction of cells with DNKv led to a significant decrease in the
number of TEM CD8
+ cells and a corresponding increase in TCM
cells, relative to the GFP control (Fig. 2C and D). However, within
the naı¨ve subset, no significant differences were observed between
DNKv1.x and GFP control cells. Similar results were observed at
an early timepoint (day3) as well as at later timepoints (days 14 and
21) (data not shown). These data show that both Kv1.3 channel
blockers and DNKv1.x transduction are capable of suppressing
the proliferation of CD8+ cells and suggest the possibility of an
effect on CD8+ T cell differentiation.
We next assessed whether blockade of Kv1.3 affected the
differentiation of naı¨ve CD8+ T cells into TEM, naı¨ve, TCM,
TEMRA and TEM. For these studies, CD8
+ cells were FACS sorted
based on their surface expression of CD8, CCR7 and CD45RA
(Fig. 3A), transduced with DN-Kv1.x or GFP control, incubated
for seven days, then analyzed for their differentiation state. Similar
to the effect on unfractionated CD8+ cells (Fig. 2C), blockade of
Kv1.3 inhibited the differentiation of the individual subsets of T
cells into TEM and/or TEMRA subsets (Fig. 3B and C). Thus, the
inactivation of Kv1.3 channel function can impair TEM differen-
tiation and proliferation. Further, transduction of TEM cells with
DNKv1.x resulted in the conversion of nearly all (.90%) the
CCR72 TEM cells to a CCR7
hi TCM phenotype. Importantly, this
reversion of TEM into TCM was stable for at least the three weeks’
assay time. In contrast, the majority of CCR72 TEM CD8 cells
transduced with the GFP control retained a classical TEM
phenotype after 3 weeks (Fig. 3D). To further confirm that the
CCR7+ cells did revert from CCR72 TEM/TEMRA cells in
DNKv1. transduced CD8 cells, we used PKH26 staining to
monitor CCR7 expression as a function of cellular division. FACS-
sorted CCR72 (TEM/TEMRA) were labeled with PKH26 and
analyzed five and eleven days after transduction for PKH26
dilution and CCR7 expression within the GFP+ cells (Fig. 3E).
While both control and Kv1.3 blocked cells initially acquired
equivalent levels of CCR7 expression, levels over time decreased
in the control cells but not in DNKv1.x cells, which suggested
a sustained reversion of CCR72 TEM into CCR7
+ cells.
Kv1.3 Blockade Suppresses Signal 1-mediated GrB
Production in CD8+ T cells
A hallmark of the CD8+ T cell activation is the production of
cytotoxic proteins such as GrB, which is critically important in the
Figure 1. Kv1.3 expression is upregulated in activated CD8+ T cells and co-localizes with CD8. (A) Purified CD8+ T cells were stimulated
with anti-CD3/CD28 for 3 days. Naı¨ve and stimulated cells were then immunostained for Kv1.3 in combination with CD8 and subsequently viewed by
immunofluorescence microscopy. Cellular nuclei were counterstained with DNA dye DAPI (blue). Kv1.3 detected by AF 594 fluorescence is shown in
red, while CD8 detected by AF 488 fluorescence is shown in green. Colocalization is indicated by a yellow and/or orange color in the overlay panels.
(B) An isotype-matched antibody was used as a negative control. Original magnification,6100. Image is representative of three different donors. (C)
Summary of percentages of activated CD8+ T cells expressing Kv1.3. In brief, 4 view fields/microscopic section were evaluated for Kv1.3+ CD8 cells
stimulated with anti-CD3/CD28 or anti-CD3 alone for 3 days. The percentages of Kv1.3+ cells are based on the number of CD8+ T cells counted. Data
are mean 6 SD from one representative of three independent and reproducible experiments. Values that are significantly different from that of non-
stimulated control are indicated as **, p,0.01.
doi:10.1371/journal.pone.0054267.g001
Kv1.3 Function in Human CD8+ T Cells
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e54267
Kv1.3 Function in Human CD8+ T Cells
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e54267
induction of efficient cytotoxicity. Because TEM/TEMRA subsets
represent a greater proportion of the GrB-secreting pool among
CD8+ T cells (Fig. S1 and Fig. S2), we reasoned that the impaired
TEM differentiation and/or a reversion of TEM into TCM might be
associated with a downregulation of GrB expression in CD8+ T
cells in which Kv1.3 signaling was blocked. As Fig. 4A demon-
strates, treatment of purified CD8+ T cells with ShK, a selective
Kv1.3 blocker, significantly inhibited anti-CD3 induced GrB
release in a dose-dependent manner, while the ability of ShK to
suppress GrB release by CD8+ T cells in response to a more potent
stimulus, anti-CD3/CD28, was not significant.
To determine the specific role of the Kv1.3 channel in
mediating GrB release, we next assessed the effects of several
different channel blockers on GrB release by CD8+ T cells at
various time points. Kv1.3 blockade was compared with two other
ion channel blockers: ChTx and TRAM-34, which are specific
blockers of KCa3.1, a Ca2+-dependent potassium channel that
dominates in activated naı¨ve and TCM subsets. MgTx and ChTx
were used at 30 nM and 50 nM, respectively which corresponded
to IC50 values in anti-CD3-induced CD8
+ T cell proliferation
(date not shown). TRAM-34 was used at 500 nM based on the
IC50 in anti-CD3-induced T cell proliferation [30]. As shown in
Fig. 4B, treatment of CD8+ T cells with either of the two Kv1.3
blockers, ShK and MgTx, resulted in significant inhibition of anti-
CD3 induced GrB production. TRAM-34 and ChTx treatment
did not affect GrB release within 24 h, but did inhibit GrB
production 48 hours after anti-CD3 stimulation. Interestingly,
although ShK inhibited anti-CD3-induced GrB release at
a comparable level to MgTx, it failed to exhibit the significant
inhibition on anti-CD3/CD28-mediated GrB release that was
observed with MgTx (Fig. 4C). It should be noted that the
inhibitory effects were not likely due to non-specific cytotoxicity by
K+ channel inhibitors, since cell viability was quite similar between
the untreated and treated groups as judged by both trypan blue
uptake and 7AAD staining. We also examined the effect of these
blockers on perforin production and found that they had no
significant effect on perforin production by either unfractioned
CD8 cells or CD8 subsets (Fig. S3).
Kv1.3 Inhibitors do not Affect CD107a Expression on
Activated CD8+ Cells
Given the possibility that the reduced GrB production by K+
channel blockers in activated CD8+ T cells might reflect a di-
minished capacity of these cells to degranulate, we evaluated the
expression levels of CD107a, which is a marker for cytotoxic CD8+
T cell degranulation [31]. As shown in Fig. 5A, surface expression
of CD107a was induced in CD8+ cells beginning two hours after
stimulation with anti-CD3/CD28 or anti-CD3 and increased
thereafter, indicating that degranulation had occurred in activated
CD8+ T cells. Analysis of the functional consequences of K+
blockade on degranulation revealed that the frequency of
CD107a+ cells presented in untreated CD8+ T cells was
comparable to that of those treated with K+ channel blockers.
Kv1.3 Blockade Ameliorates GrB-mediated Toxicity to
Neural Cells
To assess the potential functional relevance of Kv1.3 blockade
in GrB-mediated neuronal toxicity, we compared the effects of
conditioned media from activated CD8+ T cells treated with
MgTx or vehicle on neural cell viability. The results in Fig. 6A
show that cultured supernatants of activated CD8+ T cells induced
significant reduction in cell viability, as compared with non
activated CD8+ T cell-derived supernatants. The addition of
MgTx to CD8+ T cells significantly attenuated activated
conditioned T cell supernatant mediated cell toxicity. Immuno-
depletion of GrB with a specific antibody from activated CD8+ T
cell-derived supernatants demonstrated that the cell toxicity was
specifically induced by GrB (data not shown). To exclude the
possible beneficial effects on neuronal survival of residual MgTx in
the conditioned media that was added to the human neural cells
(unlikely because of its short half life), media containing the same
concentration of MgTx was incubated for 72 hours and was used
as pretreatment prior to recombinant GrB (Fig. 6B). Pretreatment
of neurons with day 3 MgTx-containing supernatants did not
block the toxic effects of GrB on neural cell neurogenesis showing
that there was no active drug in the 3 day old supernatants
transferred into the neuronal cultures.
Discussion
CD8+ T cells have been shown to contribute to autoimmune
diseases such as MS. Understanding the mechanisms by which
they mediate pathology may help to identify new targets for
therapeutic intervention. In the present studies, we confirmed our
previous finding that the Kv1.3 channel is highly expressed in the
cell membrane of activated CD8+ T cells [13], and we now show
that Kv1.3 blockade effectively inhibited proliferation of CD8+ T
cells in response to anti-CD3 alone and, in some cases, in
combination with anti-CD28. Our data further indicate that
Kv1.3 signaling is important for both differentiation of naı¨ve and
central memory into effector memory cells as well as for
maintenance of effector status. Transduction of activated CD8+
cells with DNKv1.x resulted in a significant reduction in
CCR72TEM cells, with a corresponding increase in CCR7
+
TCM cells. These results indicate a functional role of Kv1.3
channel in the regulation of proliferation as well as differentiation
of CD8+ T cells, which is important since we previously showed
that anti-proliferative drugs alone do not reproduce the conversion
to CCR7+ TCM cells seen with KvDN transduction.
Effector memory T cells are thought to be the pathogenic subset
of T cells in autoimmune diseases. Maintenance of memory cells is
likely to be a dynamic process that requires activation of a number
of signaling pathways. Our data indicate a role for Kv1.3 in this
Figure 2. Kv1.3 blockade suppresses proliferation and differentiation of anti-CD3 stimulated CD8+ T cells. (A) Freshly isolated CD8+ T
cells were pretreated with Kv channel blockers, ShK (10 nM), MgTx (30 nM) and ChTx (50 nM), for 3 hours, then stimulated with anti-CD3 alone or
anti-CD3/CD28. After 4 days of culture, proliferation was measured by [3H] thymidine uptake. Data show the mean 6 SD of three experiments.
Significant differences are marked as follows: (*, p,0.05; **, p,0.01; ***, p,0.005). (B). Isolated CD8+ T cells were labeled with PKH26 stimulated with
anti-CD3/CD28 for 24 h, and then transduced with a lentiviral vector encoding the dominant-negative Kv1.x or the GFP control alone. PKH26
fluorescence was analyzed by flow cytometry at baseline and 5 and 11 days later as shown. Quantification of proliferating cells was evaluated by
gating on PKH26high PKH26dim and PKH26low among GFP+ cells. (C). Transduced CD8+ T cells were stained with anti-CD8, anti-CCR7 or anti-
CD45RA mAbs seven days after transduction and analyzed for the percentages of naı¨ve, TCM, TEMRA and TEM cells in gated GFP+ CD8+ cells. FACS plots
shown are representative data from three separate experiments using cells from different donors. (D) The percentages of each CD8+ subset
displaying GFP fluorescence are presented as mean 6 SD of three experiments. Values that are significantly different from that of GFP control are
indicated as follows: **, p,0.01; ***, p,0.005.
doi:10.1371/journal.pone.0054267.g002
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process for CD8+ T cells. Specifically, we show that a significantly
higher proportion of DNKv1.x transduced TEM convert to
CCR7+ TCM cells as compared to GFP-control transduced TEM,
which is surprising and suggests there is more plasticity along this
lineage pathway than previously thought. Although, our data are
consistent with a recently described lineage fate mapping model of
CTLs in mice, which also found greater than 50% of TEM could
revert to TCM [32]. We recently showed that Kv1.3 blockade
causes G2 M cell cycle blockade and arrests CD4+ T cells as TCM
[33]. Taken together, these results indicate a significant role for
Kv1.3 in the proliferation and differentiation of both TEM CD4
+
and CD8+ cells.
Tissue destruction in autoimmune disease is likely to be
mediated by both CD4+ and CD8+ effector T cells, through
a variety of functions including release of proteases such as GrB.
As the majority of CD8+ T cells expressing GrB are indeed TEM
and TEMRA subpopulations of resting [34,35] and early (within 24
hours) activated CD8+ T cells selectively express high levels of
Kv1.3, we hypothesized that there might be a link between Kv1.3
expression and GrB secretion. We assessed the release of GrB after
treatment with the Kv1.3 blocker, ShK, and found a significant
decrease in GrB expression in activated CD8+ T cells, without any
significant inhibition of cell proliferation, which is consistent with
the profile of a TEM cell. These results provide a further piece of
evidence suggesting that therapeutic potential of Kv1.3 channel
blockade may mediate its effects through CD8+ T cells, as well as
CD4+ T cells. Notably Kv1.3 blockers at concentrations that
inhibit TEM cells should spare other tissues or cells, because
lymphocytes are especially susceptible due to their use of
homotetrameric Kv1.3 complexes, whereas Kv1.3 in other cell
types (e.g. neurons) is typically in heteromeric complexes.
We also found that unlike GrB, perforin was not significantly
influenced by Kv1.3 channel blockade. This observation is
consistent with reports that perforin release may occur through
different molecular pathways and that the toxicity in these cells
can be independent of perforin [16] [36], supporting an important
role for GrB in neurodegeneration.
Since T cells express two major potassium channels Kv1.3 and
KCa3.1, we sought to distinguish the unique role of Kv1.3 in GrB
production and identify whether there was an additional role for
KCa3.1, another K
+ channel known to be important in T cells.
Thus, we compared the effects of Kv1.3 channel blockers and
KCa3.1 channel blockers on GrB production in CD8
+ T cells. The
Kv1.3 channel blockers ShK and MgTx both potently inhibited
early (24 hours or less) GrB production in anti-CD3-activated
CD8+ T cells, while less on non-specific blockers that more weakly
target Kv1.3 and also KCa3.1 channels blockers did not produce
such bban effect. This result suggests that the early decrease in
GrB production detected in anti-CD3 stimulated CD8+ T cells was
specifically mediated by Kv1.3 channel inhibition on the memory
T cells, which are the only subtype of CD8+ T cells that can
produce GrB in this time frame. This finding is consistent with the
early response of TEM cells to an immune challenge in which they
initiate immediate effector functions such as cytokine secretion or
cytotoxicity [37]. In contrast, there was no inhibition of GrB
production in CD8+ T cells during the early timepoints when the
KCa3.1 channel was blocked by TRAM-34 and ChTx. As KCa3.1
acts as the functionally dominant K+ channel in naı¨ve and TCM
subsets, and is not transcriptionally up-regulated until 12 hours
after activation [4], this later inhibitory effect of TRAM-34 is most
likely due to inhibition of activated naı¨ve and TCM subsets, which
are typically not capable of immediate effector functions. Although
ChTx inhibits both Kv1.3 and KCa3.1 channels in human T
lymphocytes, its suppression of GrB release by CD8+ T cells at late
time points after anti-CD3 stimulation suggests its efficient
blocking of KCa3.1 channels is predominant, since it had no
effect on GrB production at the early timepoints (within 24 h)
when Kv1.3 is significantly upregulated. The potential relevance of
these findings is supported by both results from our previous study
[16] in which the toxicity of activated CD8 T cell supernatants to
cultured human fetal neurons was diminished when GrB was
immunodepleted, as well as the present study in which Kv1.3
blockade inhibited GrB in activated cytotoxic T cell supernatants
and decreased their toxicity to neural cells. It is worth noting that
while the present study provides evidence for the effects of these
short half-life Kv1.3 blockers on T cells, we have also previously
shown a separate effect on neuronal cell death pathways that are
regulated by Kv1.3 [15].
As activation of T cells occurs as a two-signal process, we
investigated the role of Kv1.3 blockers in the individual events of
the process. Our previous work on CD4+ T cells showed that while
the Kv1.3 channel blocker, ShK effectively inhibited anti-CD3-
induced activation and cytokine release, the addition of a potent
costimulatory signal, anti-CD28 overcame the blockade [27]. Our
present observations in which ShK suppressed early anti-CD3-
induced GrB release in CD8+ T cells, but failed to inhibit CD3/
CD28-induced GrB release suggest that a similar mechanism
could occur in CD8+ T cells as well. However, unlike ShK, MgTx
potently inhibited GrB production in CD8+ T cells induced by
anti-CD3/CD28 as well as anti-CD3 alone. Because MgTx is
chemically distinct from ShK, the differential effects of these
selective Kv1.3 blockers may imply that MgTx operates through
a different mechanism which bypasses the CD28-mediated signal,
although it may also relate to increased potency or stability of this
compound in vitro.
Further studies are required to elucidate the mechanism(s) by
which K+ channel blockers down-regulate GrB secretion in CD8+
T cells. While our results showed that K+ channel blockers do not
diminish a marker of degranulation, CD107, we did not exclude
either the possibility of a defect in the GrB production, or a later
stage of exocytosis that is independent of LAMP-1 detection in the
plasma membrane. The former mechanism, that empty granules
(not containing GrB) can be still detected by CD107a, has been
documented for CD8+ T cells that lack cytotoxic effector functions
Figure 3. Inhibitory effects of Kv1.3 blockade in the differentiation and homeostatic maintenance of TEM CD8 cells. (A) Naı¨ve, TCM,
TEMRA and TEM CD8 subpopulations were sorted from CD8+ gated cell population based on surface markers of CCR7 and CD45RA. Sorted individual
subsets within the respective gates shown were transduced with a DN-Kv1.x and GFP control. After 7 days of transfection, the percentages of each
subset in gated GFP+ CD8+ cells were analyzed by flow cytometry. Gate for expression of GFP was established using untransduced controls. (B) FACS
profiles are representative of three separate experiments using cells from different donors. The percentage of cells in each quadrant is indicated. (C)
The percentages of CD8 subsets displaying GFP fluorescence from each single transfected subpopulation are presented as mean 6 SD of three
experiments. Values that are significantly different from that of GFP control are indicated as follows: *, p,0.05, **, p,0.01; ***, p,0.005. (D)
Representative FACS profiles of phenotypical changes of transduced TCM and TEM subsets 21 days after transfection. (E). FACS-sorted CCR7- (TEM/
TEMRA) were labeled with PKH26 day (2610–6 M), followed by stimulation with anti-CD3/CD28 for 24 h and then transduced with a lentiviral vector
encoding the dominant-negative Kv1.x and GFP control alone at an MOI of ,8. PKH26 fluorescence was analyzed by flow cytometry at days 0, 5 and
11. FACS plots shown are representative data from two experiments.
doi:10.1371/journal.pone.0054267.g003
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Figure 4. K+ channel blockers inhibit GrB production by activated CD8+ T cells. Freshly isolated CD8+ T cells were pretreated with a Kv1.3
channel blocker, ShK at various concentrations (A) or with ShK (10 nM), MgTX (30 nM), ChTX (50 nM) and TRAM-34 (500 nM) (B) for 3 h, followed by
stimulation with anti-CD3/CD28 or anti-CD3 alone. The levels of GrB were measured in cell supernatants by ELISA at 6 h (A) and indicated times (B
and C). Data are mean of triplicate 6 SD of one representative of three independent and reproducible experiments. Values that are significantly
different from that of non-blocker vehicle treated control are indicated as follows: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0054267.g004
Figure 5. K+ channel blockers do not affect CD107a expression on activated CD8+ T cells. (A) Freshly isolated CD8+ T cells were
stimulated with anti-CD3/CD28 or anti-CD3 for 24 hours. Cells were then stained with a CD107a-specific mAb, or an IgG1 isotype control (filled
histogram) at the indicated times. (B). CD8+ T cells were pretreated with ShK (10 nM), MgTX (30 nM), ChTX (50 nM) and TRAM-34 (500 nM) for 3 h,
followed by stimulation with anti-CD3/CD28 or anti-CD3 alone for 6 hours. Surface expression levels of CD107a were then analyzed by flow
cytometry. FACS plots shown are representative data from three separate experiments.
doi:10.1371/journal.pone.0054267.g005
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[38]. This may suggest that the Kv1.3 inhibitory function directly
targets granule production or even GrB gene gene expression via
effects on transcription factors, such as AP-1, which is known to be
required for induction of GrB expression by antigenic stimulation
[39,40,41]. An alternative explanation for our data is the
possibility is that K+ channel blockers affect the mobilization of
intracellular free calcium ([Ca2+]i), thereby effecting later stages of
exocytosis [42,43]. We thus hypothesize that Kv1.3 blockade,
which inhibits intracellular accumulation of calcium in CTL, may
block vesicle exocytosis, but more extensive research is required to
clarify how Kv1.3 blockade may specifically target this pathway.
Our study has several limitations. As mentioned at the outset,
the autoantigen in MS is unknown and may be varied so we could
not demonstrate specificity of our findings to myelin-reactive T
cells, nor do we argue that such is the case. MBP reactive T cells
can be isolated but their precursor frequency is so low as to make
the detailed dosing and transduction experiments, described
herein, impossible. The pharmacological blockers are short-acting
and do not have sustained effects in longer in vitro assays requiring
use of the Kv1.x lentivirus system. While this provided robust
confirmation of our pharmacological data, it is arguably different
than blocking the channel pore with a small molecule inhibitor
and our data should be interpreted in that light. Finally, lentiviral
transduction seems to obviate our ability to measure intracellular
GrB thereby preventing us from asking critical questions related to
whether Kv1.3 blockade inhibits production of GrB granules or
rather just has an effect on secretion. Nonetheless, the data
presented herein significantly extend our prior report on CD8 T
cells, which was limited to physiological proof of Kv1.3 channels
on CD8 T cells and effects on proliferation, but did not examine
differentiation, reversion to Tcm, or GrB release and neurotox-
icity.
In conclusion, this study demonstrates that Kv1.3 is a compo-
nent of the pathways that regulate GrB production in activated
CD8+ T cells. While an extensive literature has documented the
role of Kv1.3 in CD4+ T cell direct effector function in
autoimmune diseases, the novel additional inhibitory effects
described herein on GrB release from CD8+ effector cells may
be especially relevant in MS, as a means of protecting neurons and
axons from direct cytoxicity [15,16].
Supporting Information
Figure S1 CD8+ T cells produce GrB in response to anti-
CD3/CD28 or anti-CD3. (A) Purified CD8+ T cells were
stimulated with anti-CD3/CD28 or anti-CD3 for 24 h (A) or in
a time course (B) Then, cell-free supernatants were collected and
assayed by ELISA for GrB secretion. Data are mean of triplicate
6 SD of one representative of three independent and reproducible
experiments. The value was significantly different from non-
stimulated control. (**, p,0.01; ***, p,0.005) (C) Flow cytometric
analysis of intracellular GrB in activated CD8+ T cells. Anti-CD3/
CD28 (red line) or anti-CD3 (green line) stimulated CD8+ T cells
were stained with a GrB-specific mAb, compared with an IgG1
isotype control (filled histogram). This figure is representative of
three different donors. (D) Purified CD8+ T cells were stimulated
with anti-CD3/CD28 for 24 h. Cells were then immunostained
for GrB (red) in combination with CD8 (green) and subsequently
viewed by immunofluorescence microscopy. Isotype control failed
to show any specific staining. Original magnification,6100. Image
is representative of three different donors.
(PPT)
Figure S2 Differential expression of GrB in CD8+ T cell
subsets. (A) Differential gating on freshly isolated CD8+ T cells
based on CCR7 and CD45RA expression revealed four popula-
tions (Naı¨ve, TCM, TEM and TEMRA) with distinct patterns of GrB
expression. (B) kinetic changes of GrB expression in CD8+ T cells
following stimulation with anti-CD3 alone or anti-CD3/CD28.
FACS profiles are representative of three different donors.
(PPT)
Figure 6. Kv1.3 channel blocker attenuates GrB mediated
neural cell toxicity. Freshly isolated human CD8+ T cells were
simulated with anti-CD3 or anti-CD3/CD28 in the presence or absence
of MgTx. Cultured supernatants were collected at 3 days after
stimulation. (A). Human neural cells cultured on poly-D-lysine pre-
coated 96 well plates were pretreated with supernatants from non-
activated CD8 T cells (Unstim.), anti-CD3 or anti-CD3/CD28-activated
CD8+ T cells without MgTx (none), and with MgTx (MgTx). After 24
hours of treatment, CellQuanti-blue dye was added in each well for 30
minutes. Fluorescence was then detected using a plate reader. Cell
viability was quantified by fluorescence intensity. (B). MgTx (30 nM) was
added to culture media and incubated for 3 days. Human NPCs were
treated with supernatants without MgTx (Ctrl), MgTx contained sups
with vehicle treatment, with GrB alone (GrB) or MgTx containing sups
plus GrB treatment (GrB/MgTx sups). Neurotoxicity was evaluated by
cell viability quantified by fluorescence intensity. The fluorescence
intensity in each group is plotted as percent relative to that in non-
activated cells (Unstim.) or control cells (Ctrl). Data are mean of triplicate
6 SD of one representative of three independent experiments. Values
that are significantly different from that of vehicle treated control are
indicated as *, p,0.05; **, p,0.01; ***, p,0.005.
doi:10.1371/journal.pone.0054267.g006
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Figure S3 K+ channel blockers do not affect perforin
production by activated CD8+ T cells. (A) Freshly isolated
CD8+ T cells and (B) FACS sorted naı¨ve, TCM, TEM (CCR7-
CD45RA-) and TEMRA (CCR7-CD45RA+) (B) were pretreated
with a Kv1.3 channel blocker, ShK at various concentrations and
at 10 nM, respectively. 3 hr after treatment, cells were stimulated
with anti-CD3/CD28 or anti-CD3 (A) and anti-CD3 alone (B).
The levels of perforin were measured in cell supernatants by
ELISA at 24 h.
(PPT)
Author Contributions
Conceived and designed the experiments: PAC LH. Performed the
experiments: LH TW HZ. Analyzed the data: LH TW. Contributed
reagents/materials/analysis tools: AN HZ JBM. Wrote the paper: LH PAC
KAW ARG.
References
1. Wulff H, Beeton C, Chandy KG (2003) Potassium channels as therapeutic
targets for autoimmune disorders. Curr Opin Drug Discov Devel 6: 640–647.
2. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, et al. (2003) The voltage-
gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin
Invest 111: 1703–1713.
3. George Chandy K, Wulff H, Beeton C, Pennington M, Gutman GA, et al.
(2004) K+ channels as targets for specific immunomodulation. Trends
Pharmacol Sci 25: 280–289.
4. Beeton C, Chandy KG (2005) Potassium channels, memory T cells, and multiple
sclerosis. Neuroscientist 11: 550–562.
5. Booss J, Esiri MM, Tourtellotte WW, Mason DY (1983) Immunohistological
analysis of T lymphocyte subsets in the central nervous system in chronic
progressive multiple sclerosis. J Neurol Sci 62: 219–232.
6. Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, et al. (2004) Multiple
sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the
cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 101: 2428–2433.
7. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, et al. (2000) Clonal
expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple
sclerosis lesions as shown by micromanipulation and single cell polymerase chain
reaction. J Exp Med 192: 393–404.
8. Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, et al. (2002) Oligoclonal
expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis
patients. Brain 125: 538–550.
9. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, et al. (2001) A pathogenic
role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp
Med 194: 669–676.
10. Steinman L (2001) Myelin-specific CD8 T cells in the pathogenesis of
experimental allergic encephalitis and multiple sclerosis. J Exp Med 194: F27–
30.
11. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, et al. (2001) Myelin
antigen-specific CD8+ T cells are encephalitogenic and produce severe disease
in C57BL/6 mice. J Immunol 166: 7579–7587.
12. Zang YC, Li S, Rivera VM, Hong J, Robinson RR, et al. (2004) Increased
CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis.
J Immunol 172: 5120–5127.
13. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, et al. (2005) The voltage-gated
potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in
multiple sclerosis brain. Proc Natl Acad Sci U S A 102: 11094–11099.
14. Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic T
lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci
25: 313–319.
15. Wang T, Allie R, Conant K, Haughey N, Turchan-Chelowo J, et al. (2006)
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor.
Faseb J 20: 1209–1211.
16. Wang T, Lee MH, Johnson T, Allie R, Hu L, et al. (2010) Activated T-cells
inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. The
Journal of neuroscience : the official journal of the Society for Neuroscience 30:
5020–5027.
17. Calabresi PA, Allie R, Mullen KM, Yun SH, Georgantas RW, 3rd, et al. (2003)
Kinetics of CCR7 expression differ between primary activation and effector
memory states of T(H)1 and T(H)2 cells. J Neuroimmunol 139: 58–65.
18. Cahalan MD, Wulff H, Chandy KG (2001) Molecular properties and
physiological roles of ion channels in the immune system. J Clin Immunol 21:
235–252.
19. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, et al. (1997) Blockade of the
voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo.
J Immunol 158: 5120–5128.
20. Garcia-Calvo M, Leonard RJ, Novick J, Stevens SP, Schmalhofer W, et al.
(1993) Purification, characterization, and biosynthesis of margatoxin, a compo-
nent of Centruroides margaritatus venom that selectively inhibits voltage-
dependent potassium channels. J Biol Chem 268: 18866–18874.
21. Price M, Lee SC, Deutsch C (1989) Charybdotoxin inhibits proliferation and
interleukin 2 production in human peripheral blood lymphocytes. Proc Natl
Acad Sci U S A 86: 10171–10175.
22. Sands SB, Lewis RS, Cahalan MD (1989) Charybdotoxin blocks voltage-gated
K+ channels in human and murine T lymphocytes. J Gen Physiol 93: 1061–
1074.
23. Deutsch C, Price M, Lee S, King VF, Garcia ML (1991) Characterization of
high affinity binding sites for charybdotoxin in human T lymphocytes. Evidence
for association with the voltage-gated K+ channel. J Biol Chem 266: 3668–3674.
24. Leonard RJ, Garcia ML, Slaughter RS, Reuben JP (1992) Selective blockers of
voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the
antiproliferative effect of charybdotoxin. Proc Natl Acad Sci U S A 89: 10094–
10098.
25. Grissmer S, Nguyen AN, Cahalan MD (1993) Calcium-activated potassium
channels in resting and activated human T lymphocytes. Expression levels,
calcium dependence, ion selectivity, and pharmacology. J Gen Physiol 102: 601–
630.
26. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, et al. (2000) Design of
a potent and selective inhibitor of the intermediate-conductance Ca2+-activated
K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A
97: 8151–8156.
27. Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA (2007)
Characterization of the functional properties of the voltage-gated potassium
channel Kv1.3 in human CD4+ T lymphocytes. Journal of immunology 179:
4563–4570.
28. Perez-Garcia MT, Lopez-Lopez JR, Riesco AM, Hoppe UC, Marban E, et al.
(2000) Viral gene transfer of dominant-negative Kv4 construct suppresses an
O2-sensitive K+ current in chemoreceptor cells. J Neurosci 20: 5689–5695.
29. Mullen KM, Rozycka M, Rus H, Hu L, Cudrici C, et al. (2006) Potassium
channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the
central nervous system. Ann Neurol 60: 118–127.
30. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, et al. (2000) Up-
regulation of the IKCa1 potassium channel during T-cell activation. Molecular
mechanism and functional consequences. J Biol Chem 275: 37137–37149.
31. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003)
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow
cytometric assay for degranulation. Journal of immunological methods 281: 65–
78.
32. Bannard O, Kraman M, Fearon DT (2009) Secondary replicative function of
CD8+ T cells that had developed an effector phenotype. Science 323: 505–509.
33. Hu L, Gocke AR, Knapp E, Rosenzweig JM, Grishkan IV, et al. (2012)
Functional blockade of the voltage-gated potassium channel Kv1.3 mediates
reversion of T effector to central memory lymphocytes through SMAD3/
p21cip1 signaling. The Journal of biological chemistry 287: 1261–1268.
34. Bratke K, Kuepper M, Bade B, Virchow JC, Jr., Luttmann W (2005) Differential
expression of human granzymes A, B, and K in natural killer cells and during
CD8+ T cell differentiation in peripheral blood. Eur J Immunol 35: 2608–2616.
35. Rock MT, Yoder SM, Wright PF, Talbot TR, Edwards KM, et al. (2005)
Differential regulation of granzyme and perforin in effector and memory T cells
following smallpox immunization. J Immunol 174: 3757–3764.
36. Kurschus FC, Bruno R, Fellows E, Falk CS, Jenne DE (2005) Membrane
receptors are not required to deliver granzyme B during killer cell attack. Blood
105: 2049–2058.
37. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of
memory T lymphocytes with distinct homing potentials and effector functions.
Nature 401: 708–712.
38. Curtsinger JM, Lins DC, Johnson CM, Mescher MF (2005) Signal 3 tolerant
CD8 T cells degranulate in response to antigen but lack granzyme B to mediate
cytolysis. Journal of immunology 175: 4392–4399.
39. Wargnier A, Legros-Maida S, Bosselut R, Bourge JF, Lafaurie C, et al. (1995)
Identification of human granzyme B promoter regulatory elements interacting
with activated T-cell-specific proteins: implication of Ikaros and CBF binding
sites in promoter activation. Proc Natl Acad Sci U S A 92: 6930–6934.
40. Babichuk CK, Duggan BL, Bleackley RC (1996) In vivo regulation of murine
granzyme B gene transcription in activated primary T cells. J Biol Chem 271:
16485–16493.
41. Babichuk CK, Bleackley RC (1997) Mutational analysis of the murine granzyme
B gene promoter in primary T cells and a T cell clone. J Biol Chem 272: 18564–
18571.
42. Menager MM, Menasche G, Romao M, Knapnougel P, Ho CH, et al. (2007)
Secretory cytotoxic granule maturation and exocytosis require the effector
protein hMunc13–4. Nature immunology 8: 257–267.
43. Takayama H, Sitkovsky MV (1987) Antigen receptor-regulated exocytosis in
cytotoxic T lymphocytes. The Journal of experimental medicine 166: 725–743.
Kv1.3 Function in Human CD8+ T Cells
PLOS ONE | www.plosone.org 12 January 2013 | Volume 8 | Issue 1 | e54267
